Stockscreener 앱 받기
1.97
0.51%
-0.01
시간 외 거래:
1.93
-0.04
-2.03%
Acelyrin Inc 주식(SLRN)의 최신 뉴스
ACELYRIN, INC. Ends Key Agreement with Affibody - TipRanks
SLRN stock touches 52-week low at $1.9 amid market challenges - MSN
JPMorgan Chase & Co. Cuts Stake in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Barclays PLC Buys 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin falls after updating mid-stage trial data for eye disease drug - MSN
Acelyrin spikes on upcoming mid-stage data update on eye disease drug - MSN
SLRN Stock Hits 52-Week Low at $2.2 Amid Market Challenges - Investing.com Nigeria
ACELYRIN reports progress in thyroid eye disease treatment By Investing.com - Investing.com Nigeria
Q1 Earnings Forecast for Acelyrin Issued By HC Wainwright - Defense World
HC Wainwright Predicts Acelyrin's Q1 Earnings (NASDAQ:SLRN) - MarketBeat
HC Wainwright Lowers Acelyrin (NASDAQ:SLRN) Price Target to $6.00 - Defense World
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - Yahoo Finance
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Citigroup Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock Price - MarketBeat
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program - Investing.com Canada
Stock market news: ACELYRIN -34.67%, Vuzix -21.58% among biggest losers during mid day trading - Business Upturn
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program By Investing.com - Investing.com South Africa
Stock market today: Acelyrin -40.40%, Amesite -30.92% among biggest losers in early trading - Business Upturn
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Acelyrin stock falls after TED drug data (SLRN:NASDAQ) - Seeking Alpha
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data - Investing.com
Jane Street Group LLC Decreases Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin stock: Piper Sandler bullish on longigutamab TED treatment potential - Investing.com India
ACELYRIN advances lonigutamab into Phase 3 for TED treatment - Investing.com India
ACELYRIN reports progress in thyroid eye disease treatment - Investing.com
Updated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease - Endpoints News
Acelyrin announces additional lonigutamab data, design for LONGITUDE program - TipRanks
Acelyrin (SLRN) Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - StreetInsider.com
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in - The Bakersfield Californian
ACELYRIN's Thyroid Eye Disease Drug Shows Promise in Phase 2, Advances to Pivotal Trials - StockTitan
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 - MSN
Acelyrin Leads The Charge With 2 Other US Penny Stocks - Yahoo Finance
Acelyrin stock spikes on upcoming data update (SLRN:NASDAQ) - Seeking Alpha
What's Going On With ACELYRIN Shares Friday? - Benzinga
Barclays PLC Purchases 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Grows Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - The Manila Times
ACELYRIN to Present Pivotal Phase 2 Data for Breakthrough Thyroid Eye Disease Treatment - StockTitan
SLRN stock touches 52-week low at $3.06 amid market challenges - Investing.com Australia
Franklin Resources Inc. Grows Stake in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
3.95%
2.39%
자본화:
|
볼륨(24시간):